JP2006506384A - 肥満の治療のためのメラノコルチン受容体リガンドとしての2−アルキル−(2−アミノ−3−アリール−プロピオニル)−ピペラジン誘導体及び関連化合物 - Google Patents
肥満の治療のためのメラノコルチン受容体リガンドとしての2−アルキル−(2−アミノ−3−アリール−プロピオニル)−ピペラジン誘導体及び関連化合物 Download PDFInfo
- Publication number
- JP2006506384A JP2006506384A JP2004546990A JP2004546990A JP2006506384A JP 2006506384 A JP2006506384 A JP 2006506384A JP 2004546990 A JP2004546990 A JP 2004546990A JP 2004546990 A JP2004546990 A JP 2004546990A JP 2006506384 A JP2006506384 A JP 2006506384A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- oxo
- piperazin
- methyl
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1(C)NCC(C)(*)NCC1 Chemical compound CC1(C)NCC(C)(*)NCC1 0.000 description 19
- ABICIYAKENJHPM-MOPGFXCFSA-N COC[C@@H](C1)NCCN1[C@@H](Cc1cc2ccccc2cc1)C(OC)=O Chemical compound COC[C@@H](C1)NCCN1[C@@H](Cc1cc2ccccc2cc1)C(OC)=O ABICIYAKENJHPM-MOPGFXCFSA-N 0.000 description 2
- XZKRXPZXQLARHH-CLTKARDFSA-N C=C/C=C\c1ccccc1 Chemical compound C=C/C=C\c1ccccc1 XZKRXPZXQLARHH-CLTKARDFSA-N 0.000 description 1
- RHLFKUNMXAOPRA-UHFFFAOYSA-N C=CCC(C1O)NCCC1=C Chemical compound C=CCC(C1O)NCCC1=C RHLFKUNMXAOPRA-UHFFFAOYSA-N 0.000 description 1
- AQRUAXDSGRHIOR-HBAHIDOBSA-N C=CC[C@@H](C[C@H](C1)OCc2ccccc2)N1C([C@@H](Cc(cc1)ccc1F)NC(C(C1)NCc2c1cccc2)=O)=O Chemical compound C=CC[C@@H](C[C@H](C1)OCc2ccccc2)N1C([C@@H](Cc(cc1)ccc1F)NC(C(C1)NCc2c1cccc2)=O)=O AQRUAXDSGRHIOR-HBAHIDOBSA-N 0.000 description 1
- ZEFQAWMPAJUAAS-IPIHXWDDSA-N CC(C)(C)OC(N(Cc1c(C2)cccc1)C2C(N[C@H](Cc(cc1)ccc1F)C(N(C1)[C@@H](CC=C)C[C@H]1OCc1ccccc1)=O)=O)=O Chemical compound CC(C)(C)OC(N(Cc1c(C2)cccc1)C2C(N[C@H](Cc(cc1)ccc1F)C(N(C1)[C@@H](CC=C)C[C@H]1OCc1ccccc1)=O)=O)=O ZEFQAWMPAJUAAS-IPIHXWDDSA-N 0.000 description 1
- NCMQKDCCSIFCGV-OCBJUFRSSA-N CC(C)(C)OC(N[C@H](Cc(cc1)ccc1F)C(N(CC1)[C@@H](COC)CN1[C@@H](Cc1cc2ccccc2cc1)C(OC)=O)=O)=O Chemical compound CC(C)(C)OC(N[C@H](Cc(cc1)ccc1F)C(N(CC1)[C@@H](COC)CN1[C@@H](Cc1cc2ccccc2cc1)C(OC)=O)=O)=O NCMQKDCCSIFCGV-OCBJUFRSSA-N 0.000 description 1
- RCXSXRAUMLKRRL-LLVKDONJSA-N CC(C)(C)OC(N[C@H](Cc(cc1)ccc1F)C(O)=O)=O Chemical compound CC(C)(C)OC(N[C@H](Cc(cc1)ccc1F)C(O)=O)=O RCXSXRAUMLKRRL-LLVKDONJSA-N 0.000 description 1
- KVPZSRWPDYRSRG-UHFFFAOYSA-N CC(C)(CO1)N(C)C1=O Chemical compound CC(C)(CO1)N(C)C1=O KVPZSRWPDYRSRG-UHFFFAOYSA-N 0.000 description 1
- RZKBOERJAHQZOB-OBRDOTTPSA-N CCC(C(NC([C@H](C)C1CC(CCCC2)=C2CC1)C(C(C1)C1I)=O)=O)N Chemical compound CCC(C(NC([C@H](C)C1CC(CCCC2)=C2CC1)C(C(C1)C1I)=O)=O)N RZKBOERJAHQZOB-OBRDOTTPSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N CCc1ccccc1 Chemical compound CCc1ccccc1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- JTPZTKBRUCILQD-UHFFFAOYSA-N CN(CCN1)C1=O Chemical compound CN(CCN1)C1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N CN(CCN1C)C1=O Chemical compound CN(CCN1C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- VWIIJDNADIEEDB-UHFFFAOYSA-N CN(CCO1)C1=O Chemical compound CN(CCO1)C1=O VWIIJDNADIEEDB-UHFFFAOYSA-N 0.000 description 1
- LDCZNQDGNSDVRH-ZEQRLZLVSA-N COC([C@H](Cc1cc2ccccc2cc1)N(CCN([C@H]1CC=C)S(c2ccccc2[N+]([O-])=O)(=O)=O)C1=O)=O Chemical compound COC([C@H](Cc1cc2ccccc2cc1)N(CCN([C@H]1CC=C)S(c2ccccc2[N+]([O-])=O)(=O)=O)C1=O)=O LDCZNQDGNSDVRH-ZEQRLZLVSA-N 0.000 description 1
- WJJRDQQSLKFKAM-OALUTQOASA-N COC([C@H](Cc1cc2ccccc2cc1)N(CCN[C@H]1CC=C)C1=O)=O Chemical compound COC([C@H](Cc1cc2ccccc2cc1)N(CCN[C@H]1CC=C)C1=O)=O WJJRDQQSLKFKAM-OALUTQOASA-N 0.000 description 1
- WMLDCWWNJOWITP-VWNXMTODSA-N COC[C@@H](CN(CC1)[C@@H](Cc2cc3ccccc3cc2)C(OC)=O)N1S(c1ccccc1[N+]([O-])=O)(=O)=O Chemical compound COC[C@@H](CN(CC1)[C@@H](Cc2cc3ccccc3cc2)C(OC)=O)N1S(c1ccccc1[N+]([O-])=O)(=O)=O WMLDCWWNJOWITP-VWNXMTODSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42057802P | 2002-10-23 | 2002-10-23 | |
PCT/US2003/033402 WO2004037797A2 (en) | 2002-10-23 | 2003-10-22 | 2 - alkyl - (2 - amino - 3 - aryl - propionyl) - piperazine derivatives and related compounds as melanocortin receptor ligands for the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006506384A true JP2006506384A (ja) | 2006-02-23 |
Family
ID=32176593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004546990A Pending JP2006506384A (ja) | 2002-10-23 | 2003-10-22 | 肥満の治療のためのメラノコルチン受容体リガンドとしての2−アルキル−(2−アミノ−3−アリール−プロピオニル)−ピペラジン誘導体及び関連化合物 |
Country Status (18)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101478253B1 (ko) * | 2007-09-17 | 2014-12-31 | 국민대학교산학협력단 | 아룸 팔래스티눔(Arum palaestinunBoiss) 유래 항암용 피페라지움 화합물 |
WO2017022733A1 (ja) * | 2015-08-04 | 2017-02-09 | アステラス製薬株式会社 | ピペラジン誘導体 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2574156A1 (en) | 2004-07-19 | 2006-02-23 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
CA2743489A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011016576A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Alanine derivatives as inhibitors of apoptosis proteins |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US9321749B1 (en) | 2012-07-25 | 2016-04-26 | Globavir Biosciences, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4251438A (en) | 1979-06-14 | 1981-02-17 | The Upjohn Company | Piperazinone and piperazine polypeptides |
US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
WO1994013696A1 (en) | 1992-12-11 | 1994-06-23 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
US5556853A (en) * | 1993-10-29 | 1996-09-17 | Takeda Chemical Industries, Ltd. | Epoxysuccinic acid derivatives |
US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
AU3128195A (en) | 1994-07-20 | 1996-02-16 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
US5767118A (en) | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
ES2235171T3 (es) | 1995-05-29 | 2005-07-01 | Pfizer Inc. | Dipeptidos que promueven la liberacion de la hormona de crecimiento. |
GB9612276D0 (en) | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
US5804578A (en) | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
AU4342097A (en) | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
US5965565A (en) | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
GB9709972D0 (en) | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
US6127381A (en) | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
RU2243215C2 (ru) | 1998-05-11 | 2004-12-27 | Ново Нордиск А/С | Производные пиперидинкарбоновых кислот, фармацевтические композиции, содержащие их, способ стимуляции секреции гормона роста |
US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
EP1085869A4 (en) | 1998-06-11 | 2001-10-04 | Merck & Co Inc | SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS |
EP1122242B1 (en) | 1998-09-22 | 2008-01-16 | Astellas Pharma Inc. | Cyanophenyl derivatives |
DK1175401T3 (da) | 1999-05-04 | 2005-11-14 | Schering Corp | Piperazinderivater, der er nyttige som CCR5-antagonister |
AU766191B2 (en) | 1999-06-04 | 2003-10-09 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
AU6000200A (en) | 1999-07-16 | 2001-02-05 | Biocompatibles Limited | Braided stent |
US6458790B2 (en) | 2000-03-23 | 2002-10-01 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
WO2001070337A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
AU6497701A (en) | 2000-05-30 | 2001-12-11 | Merck & Co Inc | Melanocortin receptor agonists |
BR0111567A (pt) | 2000-06-28 | 2003-05-06 | Pfizer Prod Inc | Ligandos do receptor de melanocortina |
JP2004506687A (ja) | 2000-08-23 | 2004-03-04 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
DE60205727T2 (de) | 2001-01-23 | 2006-06-29 | Eli Lilly And Co., Indianapolis | Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors |
US7169777B2 (en) * | 2001-01-23 | 2007-01-30 | Eli Lilly And Company | Melanocortin receptor agonists |
CA2433025A1 (en) | 2001-01-23 | 2002-08-01 | Chaoyu Xie | Substituted piperidines/piperazines as melanocortin receptor agonists |
US7015235B2 (en) | 2001-02-28 | 2006-03-21 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
EP1383501B1 (en) | 2001-02-28 | 2007-04-04 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
HUP0303484A2 (hu) | 2001-03-02 | 2004-01-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
KR100613528B1 (ko) | 2001-03-29 | 2006-08-16 | 쉐링 코포레이션 | Ccr5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 |
US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
PL369108A1 (en) | 2001-09-06 | 2005-04-18 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
US20030158209A1 (en) * | 2001-10-09 | 2003-08-21 | Neurocrine Biosciences Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
BR0213452A (pt) | 2001-10-22 | 2004-11-09 | Pfizer Prod Inc | Derivados de piperazina com atividade antagonista receptora de ccr1 |
JP2005527492A (ja) | 2002-01-23 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニスト |
-
2003
- 2003-10-20 TW TW092129035A patent/TW200504033A/zh unknown
- 2003-10-20 US US10/689,022 patent/US7132539B2/en not_active Expired - Fee Related
- 2003-10-22 MX MXPA05004378A patent/MXPA05004378A/es unknown
- 2003-10-22 RU RU2005111967/04A patent/RU2005111967A/ru not_active Application Discontinuation
- 2003-10-22 CN CNA2003801009342A patent/CN1703221A/zh active Pending
- 2003-10-22 CA CA002501231A patent/CA2501231A1/en not_active Abandoned
- 2003-10-22 JP JP2004546990A patent/JP2006506384A/ja active Pending
- 2003-10-22 WO PCT/US2003/033402 patent/WO2004037797A2/en active Application Filing
- 2003-10-22 BR BR0315614-1A patent/BR0315614A/pt not_active IP Right Cessation
- 2003-10-22 PE PE2003001070A patent/PE20040778A1/es not_active Application Discontinuation
- 2003-10-22 PL PL376702A patent/PL376702A1/pl not_active Application Discontinuation
- 2003-10-22 AU AU2003286557A patent/AU2003286557A1/en not_active Abandoned
- 2003-10-22 AR ARP030103859A patent/AR043054A1/es not_active Application Discontinuation
- 2003-10-22 KR KR1020057006836A patent/KR20050072445A/ko not_active Application Discontinuation
- 2003-10-22 EP EP03777759A patent/EP1556361A2/en not_active Withdrawn
-
2005
- 2005-04-12 ZA ZA200502944A patent/ZA200502944B/en unknown
- 2005-04-25 MA MA28235A patent/MA27478A1/fr unknown
- 2005-05-23 NO NO20052476A patent/NO20052476D0/no not_active Application Discontinuation
-
2006
- 2006-06-23 US US11/473,972 patent/US20060247224A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101478253B1 (ko) * | 2007-09-17 | 2014-12-31 | 국민대학교산학협력단 | 아룸 팔래스티눔(Arum palaestinunBoiss) 유래 항암용 피페라지움 화합물 |
WO2017022733A1 (ja) * | 2015-08-04 | 2017-02-09 | アステラス製薬株式会社 | ピペラジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP1556361A2 (en) | 2005-07-27 |
NO20052476L (no) | 2005-05-23 |
AU2003286557A1 (en) | 2004-05-13 |
PL376702A1 (pl) | 2006-01-09 |
CA2501231A1 (en) | 2004-05-06 |
NO20052476D0 (no) | 2005-05-23 |
WO2004037797A3 (en) | 2004-11-04 |
KR20050072445A (ko) | 2005-07-11 |
CN1703221A (zh) | 2005-11-30 |
WO2004037797A2 (en) | 2004-05-06 |
US20050010031A1 (en) | 2005-01-13 |
US7132539B2 (en) | 2006-11-07 |
TW200504033A (en) | 2005-02-01 |
US20060247224A1 (en) | 2006-11-02 |
PE20040778A1 (es) | 2004-12-21 |
MA27478A1 (fr) | 2005-08-01 |
BR0315614A (pt) | 2005-08-30 |
RU2005111967A (ru) | 2006-01-20 |
ZA200502944B (en) | 2006-02-22 |
AR043054A1 (es) | 2005-07-13 |
MXPA05004378A (es) | 2005-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006506384A (ja) | 肥満の治療のためのメラノコルチン受容体リガンドとしての2−アルキル−(2−アミノ−3−アリール−プロピオニル)−ピペラジン誘導体及び関連化合物 | |
KR100662309B1 (ko) | 멜라노코르틴 수용체 리간드 | |
ES2315390T3 (es) | Piperazinas sustituidas como moduladores del receptor de melanocortina. | |
US20050171158A1 (en) | Melanocortin receptor ligands | |
AU2002326469A1 (en) | Substituted piperazines as modulators of the melanocortin receptor | |
AU2002254744A1 (en) | Melanocortin receptor ligands | |
JP2005504028A (ja) | メラノコルチン受容体の調節剤としての置換ピペリジン類 | |
JP2005525410A (ja) | 摂食異常の治療のためのメラノコルチン受容体リガンドとしての使用のためのn−アシルピペラジン誘導体 | |
US20150329522A1 (en) | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | |
EP2294051B1 (en) | Alpha-substituted n-sulfonyl gylcine amides antagonists of ccr10, compositions containing the same and methods for using them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090501 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091016 |